PREIRRADIATION METHOTREXATE CHEMOTHERAPY OF PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - LONG-TERM OUTCOME
PREIRRADIATION METHOTREXATE CHEMOTHERAPY OF PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - LONG-TERM OUTCOME
复制标题
DOI：
10.3171/jns.1994.81.2.0188
复制
发表时间：
1994-08-01
影响因子：
4.1
通讯作者：
HOCHBERG, FH
中科院分区：
文献类型：
--
作者：
GLASS, J;GRUBER, ML;HOCHBERG, FH
在全脑放射治疗（WBRT）之前用化疗治疗原发性中枢神经系统淋巴瘤，可以大大改善这种先前致命疾病的结果。在最初接受治疗的 13 名患者中，有 12 名患者对静脉注射甲氨蝶呤（3.5 克/平方米，每 3 周使用甲酰四氢叶酸救援，持续 2 至 4 个周期）出现完全或部分反应。目前，共有 25 名患者（包括最初的 13 名）在 WBRT 前每 10 至 21 天接受了 1 至 6 个周期的甲氨蝶呤治疗。 22 人有部分或完全缓解，中位缓解持续时间为 32 个月。中位生存时间为 33 个月（对治疗有反应的患者为 42.5 个月）。治疗后 9 至 122 个月内，9 名患者仍存活且没有疾病证据。急性和长期毒性很小。 WBRT 之前全身给予甲氨蝶呤具有良好的耐受性并可实现长期生存。
The treatment of primary central nervous system lymphoma with chemotherapy prior to whole-brain radiation therapy (WBRT) has improved outcome considerably in this previously fatal disease. Complete or partial responses to intravenous methotrexate (3.5 gm/sq m with leucovorin rescue every 3 weeks for two to four cycles) were seen in 12 of 13 patients originally treated. A total of 25 patients (including the original 13) have now been treated with one to six cycles of methotrexate every 10 to 21 days prior to WBRT. Twenty-two had partial or complete responses, with a median duration of response of 32 months. Median survival time was 33 months (42.5 months in those responding to therapy). Nine patients are alive and without evidence of disease 9 to 122 months following therapy. Acute and long-term toxicities were minimal. Systemic methotrexate administration prior to WBRT is well tolerated and produces long-term survival.